Dr. VIVIDHA DUBEY
Rectal cancer is a significant health concern worldwide, accounting for a substantial portion of colorectal cancer cases. Over the years, the treatment landscape for rectal cancer has witnessed significant advancements, with radiation therapy playing a crucial role in improving outcomes. Here is the evolving role of radiation therapy in managing rectal cancer, highlighting the latest developments and their impact on patient care.
Neoadjuvant Radiation Therapy
Neoadjuvant radiation therapy, delivered before surgery, has become a standard approach in managing locally advanced rectal cancer. By using radiation therapy to shrink tumors, this strategy aims to improve surgical outcomes and increase the likelihood of achieving complete tumor removal. Neoadjuvant radiation therapy, often combined with chemotherapy (chemoradiotherapy), has been shown to reduce tumor size, increase the chances of sphincter preservation, and improve overall survival rates. This approach allows for a potentially less invasive surgical procedure and better patient functional outcomes.
Total Neoadjuvant Therapy (TNT)
Total neoadjuvant therapy, also known as the “watch-and-wait” approach, is an emerging concept in managing select patients with rectal cancer. This approach involves delivering neoadjuvant chemoradiotherapy followed by close monitoring of the tumor response. Surgery may be deferred for patients who demonstrate a complete clinical response, sparing them from the potential morbidity associated with surgery. TNT has gained attention due to its potential to reduce overtreatment and improve the quality of life for patients who may not require immediate surgery. However, careful patient selection and long-term follow-up are essential in this approach.
Advances in Radiation Techniques
Radiation therapy techniques have advanced significantly, allowing for more precise tumour targeting while minimizing radiation exposure to surrounding healthy tissues. Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) are commonly used in rectal cancer treatment. These approaches enable radiation oncologists to shape the radiation beams to conform closely to the tumor, delivering higher doses while reducing toxicity to nearby critical structures. Moreover, image-guided radiation therapy (IGRT) and daily cone-beam CT imaging help ensure accurate tumor targeting, further enhancing treatment precision.
Short-course Radiation Therapy
Radiation therapy for rectal cancer traditionally involves a prolonged treatment course of 5-6 weeks. It has been explored that the feasibility of short-course radiation therapy, typically delivered over one week. This approach has shown comparable oncological outcomes to the standard long-course regimen, with the advantage of reduced treatment time. Short-course radiation therapy is particularly beneficial for patients who may face challenges accessing treatment centres or require expedited treatment due to medical or logistical reasons.
Advances in Imaging and Response Assessment
The integration of advanced imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), has significantly improved the accuracy of rectal cancer staging and response assessment to treatment. Functional imaging modalities, such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI, provide valuable information about tumor characteristics and response to therapy. These advancements enable clinicians to tailor treatment plans, monitor response during neoadjuvant therapy, and make more informed decisions regarding surgical intervention or further treatment intensification.
The evolving role of radiation therapy in managing rectal cancer has transformed the treatment landscape, offering new possibilities for improved outcomes and quality of life. Integrating these advancements into multidisciplinary care ensures personalized treatment plans and better patient selection. Moving forward, ongoing research and clinical trials will further refine our understanding of optimal radiation therapy techniques, treatment durations, and sequencing in the context of rectal cancer. Additionally, efforts should focus on long-term follow-up to assess the impact of these advancements on survival rates, local control, and quality of life.
By embracing these advances and leveraging the multidisciplinary approach, we can continue to improve the outcomes and overall well-being of patients battling rectal cancer. Through ongoing collaboration, research, and innovation, we can hope for a future where rectal cancer becomes a more manageable disease, ultimately leading to better prognosis and enhanced quality of life for patients worldwide.
(The Author is MD Radiation Oncology, Consultant – Radiation Oncology, HCG Hospitals, Bhavnagar)
